ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ifebemtinib

Also written as “IN10018”, “BI 853520” and “IN10018 in combination with PLD”.

Its studies are mostly in Ovarian Neoplasms · Neoplasms · Pancreatic Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 5 companies.

Drug pageIfebemtinib: every studyMany companies study it; this page follows only the 16 they lead. All 16 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Aug 29, 202516 company-led studies, 10 open or runningNext primary completion: Mar 24, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InxMed (Shanghai)its history only117 open or runningphase 3since Aug 29, 2025Sep 26, 2019Mar 24, 2027phase 2 · NCT06014528
Boehringer Ingelheimits history only20 open or runningphase 1since Apr 7, 2011Apr 7, 2011none ahead
Hangzhou Hanx Biopharmaceuticalsits history only11 open or runningphase 2since Nov 25, 2024Nov 25, 2024Dec 31, 2027phase 2 · NCT06708663
InventisBio11 open or runningphase 2since May 13, 2022May 13, 2022Dec 31, 2027phase 2 · NCT05379946
Shanghai Jeyou Pharmaceuticalits history only11 open or runningphase 3since Sep 13, 2026Sep 13, 2026Apr 2029phase 3 · NCT07833202
  • Named in fosun pharma’s own pipeline as IN10018 (FAK), phase 3, as of Sep 21, 2026 (source).

Also a collaborator on its studies: Ranok Therapuetics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 13, 2022First study: phase 2 study in Solid TumorFirst studyNCT05379946 · 92 enrolled · China
  2. Jan 19, 2023Named ifebemtinibINNProposed as its International Nonproprietary Name in WHO's List 128 · before, IN10018, BI 853520

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Solid TumorNCT05379946

TargetBeta

PTK2 →read by rule
“An orally bioavailable inhibitor of the non-receptor, cytoplasmic tyrosine kinase protein tyrosine kinase 2 (focal adhesion kinase 1; FAK1; FAK: PTK2) ”NCIt, by rule
“Focal adhesion kinase 1 inhibitor”ChEMBL 37, by rule

Other programs on PTK2

ProgramCompanyFurthest phaseStudies
repotrectinibruleBristol-Myers Squibbphase 39

Studies

The one study InventisBio leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05379946Solid Tumor · China2Active, not recruitingDec 31, 202792

How it is read

Names in the registry

  • “IN10018”, 8 entries
  • “BI 853520”, 2 entries
  • “IN10018 in combination with PLD”, 1 entry
  • “IN10018 in combination with RNK08954”, 1 entry
  • “IN10018 in combination with D-1553”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.